Stocks · News reference
Bernstein analyst Jeffrey Walch downgraded Alnylam Pharmaceuticals to Market Perform from Outperform, citing concerns regarding the design of the company's TRITON-CM Phase 3 trial.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-05 AccNo: 0001178670-26-000080 Size: 152 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events
Alnylam Pharmaceuticals has authorized a $1 billion share repurchase program and is initiating a transition to new commercial leadership to support its next phase of growth.
Wall Street analysts identify three Nasdaq-100 stocks with potential to double based on median target prices: CoreWeave (140% upside) as a leading AI cloud provider with strong revenue growth but profitability concerns due to high debt; Nebius Group (100% upside) as an emerging AI cloud competitor with faster revenue growth but expensive valuation; and Alnylam Pharmaceuticals (100% upside) as an RNA interference therapy leader with an attractive valuation and promising pipeline.
Alnylam Pharmaceuticals announced it will present new clinical and real-world data regarding its RNAi therapeutics at the American Heart Association (AHA) Scientific Sessions 2026 and the International Symposium on Amyloidosis (ISA) 2026.
Truist Securities has downgraded Alnylam Pharmaceuticals from Buy to Hold and reduced its price target for the company's stock.
Canaccord Genuity maintained its 'Buy' rating on Alnylam Pharmaceuticals while reducing the price target to $323 from $429.